lilly trials retatrutide Eli announced pivotal Phase III results showing its triple-agonist drug delivered up to 22.6% weight loss in two separate trials, further cementing Lilly's position at the forefront of the obesity Lilly orforglipron oral GLP-1 phase
Pay in 4 interest-free payments of $6.92 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26




























